Cargando…

Direct Comparative Effectiveness Among 3 Anti–Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis

OBJECTIVE: This study aimed to compare the clinical response at 36 months and evaluate the adverse events in a cohort of patients with rheumatoid arthritis treated with etanercept, infliximab, or adalimumab. METHODS: An observational retrospective cohort study was performed. Patients older than 18 y...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santos-Moreno, Pedro, Sánchez, Guillermo, Gómez, Danny, Bello-Gualtero, Juan, Castro, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927323/ https://www.ncbi.nlm.nih.gov/pubmed/26886438 http://dx.doi.org/10.1097/RHU.0000000000000358

Ejemplares similares

Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study
por: Santos-Moreno, Pedro, et al.
Publicado: (2019)

Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model
por: Santos-Moreno, Pedro, et al.
Publicado: (2022)

The Interaction Effect of Anti-RgpA and Anti-PPAD Antibody Titers: An Indicator for Rheumatoid Arthritis Diagnosis
por: Castillo, Diana Marcela, et al.
Publicado: (2023)

From the model of integral attention to the creation of centers of excellence in rheumatoid arthritis
por: Santos-Moreno, Pedro, et al.
Publicado: (2015)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Predictive factors related to the progression of periodontal disease in patients with early rheumatoid arthritis: a cohort study
por: Heredia-P, Ana María, et al.
Publicado: (2019)

High Levels of Leptin and Adipsin Are Associated with Clinical Activity in Early Rheumatoid Arthritis Patients with Overweight and Periodontal Infection
por: Romero-Sánchez, Consuelo, et al.
Publicado: (2023)

Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
por: Julià, Antonio, et al.
Publicado: (2021)

Evaluation of the adipokine profile (adiponectin, resistin, adipsin, vaspin, and leptin) in patients with early rheumatoid arthritis and its correlation with disease activity
por: Magali Chamorro-Melo, Yany, et al.
Publicado: (2022)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Development of Rheumatoid Nodules after Anti-Tumor Necrosis Factor-α Treatment with Adalimumab for Rheumatoid Arthritis
por: Shin, Sungsik, et al.
Publicado: (2016)

Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis
por: de Castro, Caroline Tianeze, et al.
Publicado: (2022)

Real-world retention rates of biologics in patients with rheumatoid arthritis
por: Takami, Kenji, et al.
Publicado: (2023)

Prevalence of Sexual Disorders in Patients With Rheumatoid Arthritis and Associated Factors
por: Santos-Moreno, Pedro, et al.
Publicado: (2020)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis
por: Martínez-Santana, Virginia, et al.
Publicado: (2013)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
por: Choy, Ernest H., et al.
Publicado: (2017)

Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2004)

Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review
por: Davignon, Jean-Luc, et al.
Publicado: (2018)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Life-Threatening Gastrointestinal Mucosal Necrosis during Methotrexate Treatment for Rheumatoid Arthritis
por: Tsukada, Tomoya, et al.
Publicado: (2013)

Clinical Outcomes of Patients with Rheumatoid Arthritis Treated in a Disease Management Program: Real-World Results
por: Santos-Moreno, Pedro, et al.
Publicado: (2020)

Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis
por: Paula, Filipe Seguro, et al.
Publicado: (2013)

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
por: Hueber, Wolfgang, et al.
Publicado: (2009)

Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis
por: Kapoor, Sabrina R, et al.
Publicado: (2013)

Ulcerative necrobiosis lipoidica in the setting of anti–tumor necrosis factor-α and hydroxychloroquine treatment for rheumatoid arthritis
por: Fehlman, Jennifer Albus, et al.
Publicado: (2017)

Weight Gain in Seropositive Rheumatoid Arthritis Patients Treated With Anti-tumor Necrosis Factor (TNF) Therapy
por: Alsulaim, Toka M, et al.
Publicado: (2022)

Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor
por: Conigliaro, Paola, et al.
Publicado: (2016)

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting
por: de Camargo, Mayara Costa, et al.
Publicado: (2019)

Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis
por: Corrado, Addolorata, et al.
Publicado: (2017)

TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy
por: Canhão, Helena, et al.
Publicado: (2015)

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
por: Cannon, Grant W., et al.
Publicado: (2016)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2015)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
por: Reed, George W., et al.
Publicado: (2019)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Wang, Chrong-Reen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_umv88uricq2fl8jou7mlkqunbg